BREO Ellipta 藥物市場：按作用機制、適應症和最終用戶分類 - 2026-2032 年全球市場預測

2025 年 BREO Ellipta 製藥市值為 33.3 億美元，預計到 2026 年將成長至 34.7 億美元，複合年成長率為 4.68%，到 2032 年將達到 45.9 億美元。

主要市場統計數據
基準年 2025	33.3億美元
預計年份：2026年	34.7億美元
預測年份 2032	45.9億美元
複合年成長率 (%)	4.68%

BREO Ellipta 療法在臨床實踐中的策略性引入概述了其藥理學、臨床效用以及在設備和藥物依從性方面的差異化優勢。

本執行導言概述了 BREO Ellipta 療法在現代呼吸醫學中的臨床特徵和策略意義。

呼吸照護路徑的演變以個人化指南、數位化用藥依從性技術、供應鏈韌性和對永續性的重視為驅動。

呼吸醫學領域正在經歷一場變革，其驅動力包括不斷演變的指南、新技術的引入以及對以患者為中心的護理路徑的重新關注。

本研究評估了 2025 年價格調整將如何影響吸入療法的藥品採購、生產在地化、價格談判和供應彈性。

2025 年美國將實施的價格政策變更的累積影響將對吸入療法的藥品供應鏈、定價策略和商業性實施產生重大影響。

全面的細分分析揭示了作用機制、臨床適應症的多樣性以及最終用戶的醫療保健環境如何決定引入途徑和商業策略。

關鍵的細分洞察揭示了治療機制、臨床適應症和護理環境如何全面影響採用動態和商業性重點。

制定區域策略，以協調美洲、歐洲、中東、非洲和亞太地區的監管合作、為支付者提供證據以及供應鏈韌性。

區域趨勢對美洲、歐洲、中東和非洲以及亞太地區的監管策略、報銷管道和臨床引入有重大影響。

競爭情報和商業情報重點在於生命週期策略、夥伴關係、數位化藥物合規性和生產韌性如何決定公司的市場定位。

老牌製造商和新興企業之間的競爭動態正在重塑產品定位、生命週期策略和夥伴關係模式。

產業領導者正在採取切實可行的策略措施，以增強其吸入療法產品組合的市場進入，確保供應彈性，並提高患者的依從性。

這些切實可行的建議為尋求加強自身地位並加速吸入療法持續普及的行業領導者提供了切實可行的藍圖。

本節介紹了一種混合方法研究途徑，該方法結合了對臨床醫生的訪談、二手文獻的整合以及多階段檢驗，以得出可靠的研究結果。

本調查方法結合了原始質性資料、系統性的二手文獻綜述和嚴格的檢驗，以確保研究結果的可靠性和可操作性。

綜合臨床趨勢、商業性需求和營運重點，總結出有助於制定吸入療法策略決策的結論。

總之，BREO Ellipta 療法及相關吸入性聯合治療的未來發展前景受臨床進展、商業性壓力和營運挑戰的影響，這些因素共同決定了策略重點。

目錄

第1章：序言

第2章：調查方法

• 調查設計
• 研究框架
• 市場規模預測
• 數據三角測量
• 調查結果
• 調查的前提
• 研究限制

第3章執行摘要

• 首席主管觀點
• 市場規模和成長趨勢
• 2025年市佔率分析
• FPNV定位矩陣，2025
• 新的商機
• 下一代經營模式
• 產業藍圖

第4章 市場概覽

• 產業生態系與價值鏈分析
• 波特五力分析
• PESTEL 分析
• 市場展望
• 市場進入策略

第5章 市場洞察

• 消費者洞察與終端用戶觀點
• 消費者體驗基準
• 機會映射
• 分銷通路分析
• 價格趨勢分析
• 監理合規和標準框架
• ESG與永續性分析
• 中斷和風險情景
• 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：BREO Ellipta藥物市場及其作用機制

• ICS
• LAMA
• LABA

第9章：BREO Ellipta藥物市場：依適應症分類

• 氣喘
• 氣喘/慢性阻塞性肺病重疊症候群
• COPD

第10章：BREO Ellipta 製藥市場：依最終用戶分類

• 居家醫療
• 醫院
• 專科診所

第11章 BREO Ellipta 製藥市場：按地區分類

• 北美洲和南美洲
  • 北美洲
  • 拉丁美洲
• 歐洲、中東和非洲
  • 歐洲
  • 中東
  • 非洲
• 亞太地區

第12章 BREO Ellipta 製藥市場：依組別分類

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第13章 BREO Ellipta 製藥市場：依國家分類

• 美國
• 加拿大
• 墨西哥
• 巴西
• 英國
• 德國
• 法國
• 俄羅斯
• 義大利
• 西班牙
• 中國
• 印度
• 日本
• 澳洲
• 韓國

第14章：美國 BREO Ellipta 製藥市場

第15章：中國 BREO Ellipta 藥廠

第16章 競爭格局

• 市場集中度分析，2025年
  • 濃度比（CR）
  • 赫芬達爾-赫希曼指數 (HHI)
• 近期趨勢及影響分析，2025 年
• 2025年產品系列分析
• 基準分析，2025 年
• AstraZeneca plc
• Boehringer Ingelheim International GmbH
• CHIESI Farmaceutici SpA
• Cipla Limited
• GlaxoSmithKline plc
• Hikma Pharmaceuticals PLC
• Lupin Pharmaceuticals, Inc.
• Merck & Co., Inc.
• Novartis AG
• Orion Corporation
• Teva Pharmaceutical Industries Ltd.

The BREO Ellipta Drugs Market was valued at USD 3.33 billion in 2025 and is projected to grow to USD 3.47 billion in 2026, with a CAGR of 4.68%, reaching USD 4.59 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 3.33 billion
Estimated Year [2026]	USD 3.47 billion
Forecast Year [2032]	USD 4.59 billion
CAGR (%)	4.68%

A strategic introduction that situates BREO Ellipta therapies within clinical practice by outlining pharmacology, real-world utility, and differentiating device and adherence advantages

This executive introduction frames the clinical profile and strategic significance of BREO Ellipta therapies within contemporary respiratory medicine.

BREO Ellipta, a once-daily fixed-dose inhaled combination, integrates an inhaled corticosteroid with a long-acting beta2-agonist to deliver convenient, adherence-friendly therapy for airway inflammatory disease. Clinically, the formulation targets both maintenance therapy for asthma and the chronic management of COPD where anti-inflammatory control and bronchodilation are central to symptom reduction and exacerbation prevention. The dry powder inhaler device platform supports standardized dosing, ease of use for many patients, and compatibility with patient education programs designed to improve long-term adherence.

From a strategic lens, this product class occupies an intersection of established pharmacology and evolving therapeutic expectations. Payers and providers increasingly evaluate therapies on their real-world effectiveness, safety profile, and capacity to reduce acute care utilization. Consequently, clinical differentiators such as dosing frequency, inhaler ergonomics, and the robustness of post-marketing safety data materially shape clinician prescribing behavior and formulary positioning. Furthermore, lifecycle management opportunities-ranging from label expansions to device enhancements-remain central to sustaining therapeutic relevance amidst intensifying competition and shifting care models.

Evolving respiratory care pathways driven by guideline personalization, digital adherence technologies, supply chain resilience, and sustainability priorities

The respiratory landscape is undergoing transformative shifts driven by guideline evolution, technology adoption, and a renewed focus on patient-centric care pathways.

Guideline updates increasingly emphasize personalized approaches that match inhaled controller intensity to individual risk profiles, spurring greater interest in both dual and triple combination regimens for patients whose symptoms and exacerbation history justify escalated therapy. At the same time, technological innovation-ranging from connected inhaler sensors to telehealth-enabled adherence programs-has changed how clinicians monitor and support patients, enabling more proactive interventions and data-driven treatment optimization. These digital adjuncts also create new value propositions for therapeutics, linking pharmacologic effect with measurable improvements in daily inhaler use.

Supply chain resilience and environmental considerations are reshaping procurement and formulary choices. Manufacturers and healthcare systems are prioritizing sourcing strategies that mitigate disruption risk while also responding to institutional sustainability targets. In parallel, payers are intensifying scrutiny of long-term outcomes and total cost of care, encouraging manufacturers to demonstrate not only clinical efficacy but also economic value in real-world settings. As a result, successful products increasingly combine clinical excellence with pragmatic delivery and commercial strategies that align with evolving healthcare priorities.

Assessing how 2025 tariff changes reshape pharmaceutical sourcing, manufacturing localization, pricing negotiations, and supply resilience for inhaled therapies

The cumulative impact of tariff policy shifts implemented in the United States in 2025 has important implications for pharmaceutical supply chains, pricing strategies, and commercial execution for inhaled therapies.

Tariff adjustments that affect imported pharmaceutical ingredients, device components, and packaging materials introduce added cost volatility and compel manufacturers to reassess sourcing strategies. In response, companies are accelerating localization of key manufacturing steps, diversifying supplier portfolios, and renegotiating long-term contracts to insulate margins and maintain predictable supply. These operational changes, in turn, influence inventory planning and the cadence of product launches in affected markets. For manufacturers that rely on cross-border supply chains for active pharmaceutical ingredients or specialized inhaler components, the need for contingency planning has become a front-line commercial priority.

Beyond manufacturing, tariff-driven cost pressures can reshape pricing and reimbursement negotiations. Payers and providers may-expect greater transparency on cost drivers and may push for value-based arrangements that tie payment to patient outcomes. Consequently, commercial teams must prepare evidence dossiers that demonstrate clinical benefit and downstream cost offsets, and they must model scenarios that reflect potential supply chain cost pass-throughs. Strategic responses also include investment in manufacturing redundancy, selective onshoring of critical components, and closer collaboration with distributors and wholesalers to smooth logistical impacts on product availability.

Comprehensive segmentation analysis revealing how mechanism of action, clinical indication diversity, and end-user care settings define adoption pathways and commercial tactics

Key segmentation insights reveal how therapeutic mechanism, clinical indication, and points of care collectively shape adoption dynamics and commercial prioritization.

Based on mechanism of action, the therapeutic landscape spans inhaled corticosteroids (ICS), combined ICS/LABA regimens exemplified by fluticasone furoate vilanterol, triple-combination ICS/LAMA/LABA formulations such as fluticasone furoate umeclidinium vilanterol, as well as standalone bronchodilator classes that include LABA, LAMA with agents like umeclidinium, and dual LAMA/LABA combinations such as umeclidinium vilanterol. Within this structure, ICS/LABA combinations remain central for many patients due to their established anti-inflammatory and bronchodilatory synergy, while interest in triple therapies has risen for patients with persistent symptoms or frequent exacerbations, emphasizing the importance of comparative effectiveness data in shaping clinical decision-making.

Based on indication, the therapeutic focus spans asthma, asthma-COPD overlap presentations, and COPD as distinct clinical pathways with different therapeutic thresholds and monitoring priorities. Asthma management continues to emphasize stepwise escalation and de-escalation to balance control and safety, while COPD treatment paradigms tilt toward maximizing symptom control and minimizing exacerbation risk. Overlap phenotypes present additional complexity, requiring careful phenotyping and individualized therapy choices that often benefit from integrated care pathways and specialist input.

Based on end user, care delivery settings include homecare programs, hospitals, and specialty clinics, each with unique operational drivers. Homecare and outpatient management increasingly incorporate remote monitoring and patient education to support adherence and reduce acute visits, whereas hospitals and specialty clinics play a pivotal role in initiating advanced regimens, conducting inhaler technique training, and managing complex comorbidities. Consequently, commercial strategies that align clinician training, patient support, and distribution across these end-user settings strengthen uptake and optimize real-world therapeutic performance.

Regional strategies that align regulatory engagement, payer evidence generation, and supply chain resilience across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics materially influence regulatory strategy, reimbursement access, and clinical adoption across the Americas, Europe, Middle East & Africa, and Asia-Pacific.

In the Americas, regulatory pathways and payer models emphasize outcome evidence and cost-effectiveness, driving manufacturers to pair clinical data with health economic analyses and patient support initiatives. The United States market in particular demands robust real-world evidence and formulary engagement strategies that address heterogenous payer requirements, while Latin American markets often reflect variability in access and procurement approaches that can favor strategic partnerships with local distributors.

Across Europe, Middle East & Africa, regulatory harmonization in some regions coexists with distinct national reimbursement frameworks that shape launch sequencing and pricing. European health systems commonly require comparative effectiveness and budget impact information for formulary inclusion, and regional sustainability initiatives can influence device choice and procurement. Meanwhile, healthcare infrastructure heterogeneity across the Middle East and Africa necessitates tailored commercial and supply approaches that accommodate variability in care delivery and procurement capacity.

In the Asia-Pacific region, rapid healthcare modernization, expanding specialist networks, and growing emphasis on chronic disease management create both opportunities and complexities. Diverse regulatory environments, varying degrees of public reimbursement, and an expanding base of patients moving into treatment paradigms drive a need for regionally adapted evidence generation and distribution strategies. Manufacturers that invest in local evidence, clinician education, and supply chain robustness are better positioned to capitalize on adoption trends across these diverse geographies.

Competitive and commercial intelligence highlighting how lifecycle strategies, partnerships, digital adherence, and manufacturing resilience define company positioning

Competitive dynamics among established manufacturers and emerging players are reshaping product positioning, lifecycle strategies, and partnership models.

Incumbent companies with established inhaled therapies are focusing on lifecycle extensions through device refinement, label updates, and real-world evidence programs that emphasize safety and long-term outcomes. At the same time, competitors are differentiating through novel combinations, alternate delivery platforms, and investments in digital adherence technologies that pair pharmacology with patient behavior management. Partnerships and alliances-ranging from co-development agreements to commercialization collaborations-have become common mechanisms to accelerate access to complementary competencies such as device engineering, digital health integration, and regional distribution networks.

Supply chain strategies and manufacturing footprint decisions also distinguish competitive approaches. Firms that proactively diversify component sourcing, adopt modular manufacturing models, and invest in regional capacity can better navigate tariff fluctuations and logistic disruptions. Commercially, companies that align pricing, patient support, and outcome measurement are more effective in payer negotiations, while those that invest in clinician education and inhaler technique training strengthen prescribing confidence and long-term adherence. Overall, competitive success increasingly rests on integrating clinical differentiation with operational excellence and value-oriented commercial models.

Practical strategic actions for industry leaders to strengthen market access, ensure supply resilience, and increase patient adherence for inhaled therapeutic portfolios

Actionable recommendations provide a pragmatic blueprint for industry leaders seeking to strengthen positioning and accelerate sustainable uptake of inhaled therapies.

First, integrate robust real-world evidence programs into launch and lifecycle strategies to demonstrate clinical and economic value across diverse care settings. Complement randomized trial data with pragmatic studies and registries that capture adherence, exacerbation rates, and healthcare utilization to support payer discussions and clinician decision-making. Second, prioritize device ergonomics and patient training as central elements of product strategy; investments in inhaler design, instructional tools, and support programs materially improve technique and adherence, which in turn drive better outcomes.

Third, diversify manufacturing and sourcing to mitigate tariff and supply chain risks by establishing regional production hubs and securing alternative suppliers for critical components. Fourth, embrace digital health adjuncts that enable remote adherence monitoring and personalized interventions, and pair these technologies with outcomes-based contracting where feasible to align value creation with reimbursement. Finally, engage early with regulatory and payer stakeholders to align evidence generation plans with approval and reimbursement requirements, ensuring smoother market access pathways and more predictable commercial rollouts. Implementing these actions in concert will strengthen resilience, enhance patient outcomes, and create defensible commercial differentiation.

Description of the mixed-methods research approach combining clinician interviews, secondary literature synthesis, and multi-stage validation to produce robust insights

The research methodology blends primary qualitative inputs, systematic secondary review, and rigorous validation to ensure credible and actionable insights.

Primary research included structured interviews with clinical specialists in respiratory medicine, pharmacy directors, hospital procurement leads, and payers to capture frontline perspectives on prescribing behavior, formulary decision drivers, and operational constraints. Secondary review encompassed peer-reviewed clinical literature, regulatory filings, device performance studies, and public policy documents to contextualize clinical and commercial trends. Evidence synthesis prioritized high-quality sources and recent publications to reflect the current therapeutic environment.

All findings underwent multi-stage validation, including cross-referencing clinician interviews with secondary data and internal expert review to ensure consistency and minimize bias. Limitations were acknowledged where data variability existed across regions or where long-term outcomes data remained emergent. The methodology emphasizes transparency in assumptions and invites stakeholders to request deeper data appendices or tailored analyses that align with specific decision-making needs.

Concluding synthesis that ties together clinical trends, commercial imperatives, and operational priorities to inform strategic decision-making for inhaled therapies

In conclusion, the landscape for BREO Ellipta therapies and related inhaled combinations is shaped by clinical evolution, commercial pressures, and operational challenges that together define strategic priorities.

Clinical practice is moving toward more personalized regimens and greater use of combined therapies where appropriate, while digital tools and adherence programs are changing how long-term control is achieved and measured. Tariff changes and supply chain considerations reinforce the need for diversified sourcing and manufacturing agility, and regional differences in regulatory and payer environments require tailored evidence generation and market access plans. Competitive advantage will accrue to organizations that integrate clinical differentiation, device and digital support, and resilient operational models that together deliver demonstrable value to patients, providers, and payers.

Looking ahead, the successful commercialization of inhaled therapies will rely as much on execution across distribution, training, and value demonstration as it does on pharmacologic efficacy. Decision-makers should therefore align clinical development, market access, and operational strategies to capture sustainable uptake and ensure that patients receive consistent, effective respiratory care.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. BREO Ellipta Drugs Market, by Mechanism Of Action

• 8.1. ICS
• 8.2. LAMA
• 8.3. LABA

9. BREO Ellipta Drugs Market, by Indication

• 9.1. Asthma
• 9.2. Asthma COPD Overlap
• 9.3. COPD

10. BREO Ellipta Drugs Market, by End User

• 10.1. Homecare
• 10.2. Hospitals
• 10.3. Specialty Clinics

11. BREO Ellipta Drugs Market, by Region

• 11.1. Americas
  • 11.1.1. North America
  • 11.1.2. Latin America
• 11.2. Europe, Middle East & Africa
  • 11.2.1. Europe
  • 11.2.2. Middle East
  • 11.2.3. Africa
• 11.3. Asia-Pacific

12. BREO Ellipta Drugs Market, by Group

• 12.1. ASEAN
• 12.2. GCC
• 12.3. European Union
• 12.4. BRICS
• 12.5. G7
• 12.6. NATO

13. BREO Ellipta Drugs Market, by Country

• 13.1. United States
• 13.2. Canada
• 13.3. Mexico
• 13.4. Brazil
• 13.5. United Kingdom
• 13.6. Germany
• 13.7. France
• 13.8. Russia
• 13.9. Italy
• 13.10. Spain
• 13.11. China
• 13.12. India
• 13.13. Japan
• 13.14. Australia
• 13.15. South Korea

14. United States BREO Ellipta Drugs Market

15. China BREO Ellipta Drugs Market

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025
• 16.5. AstraZeneca plc
• 16.6. Boehringer Ingelheim International GmbH
• 16.7. CHIESI Farmaceutici S.p.A.
• 16.8. Cipla Limited
• 16.9. GlaxoSmithKline plc
• 16.10. Hikma Pharmaceuticals PLC
• 16.11. Lupin Pharmaceuticals, Inc.
• 16.12. Merck & Co., Inc.
• 16.13. Novartis AG
• 16.14. Orion Corporation
• 16.15. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

• FIGURE 1. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL BREO ELLIPTA DRUGS MARKET SHARE, BY KEY PLAYER, 2025
• FIGURE 3. GLOBAL BREO ELLIPTA DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
• FIGURE 4. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 5. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 7. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 9. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 10. UNITED STATES BREO ELLIPTA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 11. CHINA BREO ELLIPTA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

• TABLE 1. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 2. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
• TABLE 3. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ICS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 4. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ICS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 5. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ICS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 6. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA, BY REGION, 2018-2032 (USD MILLION)
• TABLE 7. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 8. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 9. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY LABA, BY REGION, 2018-2032 (USD MILLION)
• TABLE 10. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY LABA, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 11. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY LABA, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 12. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 13. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ASTHMA, BY REGION, 2018-2032 (USD MILLION)
• TABLE 14. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ASTHMA, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 15. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ASTHMA, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 16. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ASTHMA COPD OVERLAP, BY REGION, 2018-2032 (USD MILLION)
• TABLE 17. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ASTHMA COPD OVERLAP, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 18. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ASTHMA COPD OVERLAP, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 19. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY COPD, BY REGION, 2018-2032 (USD MILLION)
• TABLE 20. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY COPD, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 21. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY COPD, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 22. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 23. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 24. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 25. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 26. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 27. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 28. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 29. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 30. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 31. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 32. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 33. AMERICAS BREO ELLIPTA DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 34. AMERICAS BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
• TABLE 35. AMERICAS BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 36. AMERICAS BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 37. NORTH AMERICA BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 38. NORTH AMERICA BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
• TABLE 39. NORTH AMERICA BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 40. NORTH AMERICA BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 41. LATIN AMERICA BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 42. LATIN AMERICA BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
• TABLE 43. LATIN AMERICA BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 44. LATIN AMERICA BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 45. EUROPE, MIDDLE EAST & AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 46. EUROPE, MIDDLE EAST & AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
• TABLE 47. EUROPE, MIDDLE EAST & AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 48. EUROPE, MIDDLE EAST & AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 49. EUROPE BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 50. EUROPE BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
• TABLE 51. EUROPE BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 52. EUROPE BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 53. MIDDLE EAST BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 54. MIDDLE EAST BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
• TABLE 55. MIDDLE EAST BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 56. MIDDLE EAST BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 57. AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 58. AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
• TABLE 59. AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 60. AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 61. ASIA-PACIFIC BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 62. ASIA-PACIFIC BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
• TABLE 63. ASIA-PACIFIC BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 64. ASIA-PACIFIC BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 65. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 66. ASEAN BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 67. ASEAN BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
• TABLE 68. ASEAN BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 69. ASEAN BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 70. GCC BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 71. GCC BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
• TABLE 72. GCC BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 73. GCC BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 74. EUROPEAN UNION BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 75. EUROPEAN UNION BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
• TABLE 76. EUROPEAN UNION BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 77. EUROPEAN UNION BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 78. BRICS BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 79. BRICS BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
• TABLE 80. BRICS BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 81. BRICS BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 82. G7 BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 83. G7 BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
• TABLE 84. G7 BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 85. G7 BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 86. NATO BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 87. NATO BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
• TABLE 88. NATO BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 89. NATO BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 90. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 91. UNITED STATES BREO ELLIPTA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 92. UNITED STATES BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
• TABLE 93. UNITED STATES BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 94. UNITED STATES BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 95. CHINA BREO ELLIPTA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 96. CHINA BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
• TABLE 97. CHINA BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 98. CHINA BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)